Q2 North America Organic Growth Turns Positive, But Europe Keeps LKQ On Hold

What happened

LKQ's Q2 results revealed its first positive North American organic growth in nine quarters, offering a glimmer of stabilization driven by increased alternative parts adoption and steady aftermarket demand. However, overall revenue still fell 6% year-over-year to $3.4 billion, and adjusted EPS declined to $0.67, as European operations continued to suffer from ERP disruptions and lost wallet share. Consolidated EBITDA margin compressed 160 basis points to 10.2%, underscoring that European headwinds are blunting North American progress. While the North American turn aligns with the awaited claim/volume stabilization, persistent European weakness and the lack of a strategic-review timetable keep the investment thesis in a holding pattern. The quarter provides early evidence of recovery in the core region but not yet enough to resolve the dual overhang of Europe and strategic uncertainty.

Implication

Investors should treat the North American organic growth recovery as a prerequisite met, though insufficient for a rating upgrade without European improvement. Europe’s ERP and wallet-share issues appear sticky, likely delaying consolidated margin recovery and keeping a cap on near-term multiple expansion. The strategic review still lacks a deadline, so event-driven upside remains uncertain and could extend the overhang. The stock is likely to trade range-bound until management demonstrates that North American momentum can translate into sustainable consolidated earnings growth or provides concrete strategic-process milestones. We maintain our WAIT rating and would look to add only on clearer evidence that the European headwinds are abating or the strategic review is advancing within the 6–12 month re-assessment window.

Thesis delta

The thesis is mildly strengthened by North American stabilization, but the European deterioration introduces a new negative offset. The core requirement—that FY2026 free cash flow stays within the $700–$850 million guide while North America volumes stop declining—has seen partial progress, leaving the WAIT rating unchanged. No shift in conviction is warranted until Europe’s challenges are resolved or the strategic process accelerates.